Research and Application Progress of Lipid-Lowering Drugs and Pharmacogenomics in Chronic Disease Management of Older People
Lipid-lowering drugs are currently recognized as the cornerstone in treating dyslipidemia.However,there are individual differences in terms of the efficacy and adverse reactions of lipid-lowering drugs,and pharmacogenomics is one of the main reasons for this difference.In order to have a more comprehensive understanding of lipid-lowering pharmacogenomics,guide the selection of lipid-lowering drugs,and provide references for improving clinical lipid-lowering efficacy and reducing toxic and side effects among the elderly population,based on the relevant literature and data at home and abroad,this paper reviewed the clinical treatment progress,pharmacogenomic technologies and application progress of statins,fibrates,niacin,ezetimibe and PCSK9 inhibitors commonly used in clinical practice.Existing studies have proved that pharmacogenomics can provide a reference for lipid-lowering precision therapy,but the clinical application of pharmacogenomics is limited due to the high cost and insufficient knowledge about pharmacogenomics.In the future,we should gradually strengthen the clinical research and knowledge popularization of pharmacogenomics to promote the rapid development of precision medicine in China.
management of chronic diseases among the elderlylipid-lowering drugspharmacogenomicsgenetic polymorphism